When market volatility kicks in, dividend-paying stocks tend to look pretty attractive. The appeal is straightforward: these companies typically generate robust free cash flow and share those profits directly with shareholders through consistent dividend payments.

Let's look at three healthcare sector stocks that combine meaningful dividend yields with recent analyst attention from Wall Street's most accurate forecasters.

Merck: The Highest-Conviction Pick

Dividend Yield: 3.06%

Merck & Co Inc (MRK) is attracting bullish commentary from analysts with strong track records. UBS analyst Trung Huynh, who has nailed stock calls 76% of the time, maintained a Buy rating and bumped the price target from $105 to $130 on January 7, 2026. That's a substantial upward revision that signals growing confidence in the pharmaceutical giant's prospects.

Not quite as enthusiastic but still constructive, Citigroup analyst Geoff Meacham (71% accuracy rate) maintained a Neutral rating while raising the price target from $95 to $110 on the same day.

The recent buzz around Merck centers on its reported acquisition talks with cancer drugmaker Revolution Medicines Inc. (RVMD). The potential deal could be valued between $28 billion and $32 billion, representing a significant bet on expanding Merck's oncology portfolio.

CVS Health: Steady Yield, Modest Growth Expectations

Dividend Yield: 3.27%

CVS Health Corp (CVS) offers the middle-ground yield in this trio, and it's getting measured optimism from well-regarded analysts. Truist Securities analyst David Macdonald, who has a 69% accuracy rate, maintained a Buy rating and increased the price target from $95 to $98 on December 10, 2026.

UBS analyst Kevin Caliendo, also sporting a 69% accuracy rate, kept his Buy rating on the stock and raised the price target from $96 to $97 on December 10, 2025. These are incremental increases rather than dramatic revisions, suggesting analysts see steady but not spectacular growth ahead.

The company announced it will hold a conference call on Tuesday, February 10, 2026, to discuss fourth quarter financial results. That earnings report could be a catalyst for the stock either direction, depending on how the retail pharmacy and insurance giant performed during the period.

GSK: Highest Yield, Mixed Signals

Dividend Yield: 3.47%

GSK plc (GSK) delivers the highest dividend yield of the three at 3.47%, but analyst opinion is more divided here. Barclays analyst James Gordon, who has a 66% accuracy rate, downgraded the stock from Equal-Weight to Underweight on January 6, 2026. That's a move to the bearish side of the ledger from a previously neutral stance.

Meanwhile, Jefferies analyst Michael Leuchten (57% accuracy rate) upgraded the stock from Hold to Buy on October 27, 2025. The divergence in views reflects different perspectives on the British pharmaceutical company's growth trajectory and competitive positioning.

On the news front, Summit Therapeutics announced on January 12 a clinical trial collaboration with GSK to evaluate ivonescimab in combination with GSK's B7-H3 antibody drug conjugate. These kinds of partnerships can enhance a company's drug development pipeline without massive upfront capital expenditures.

Why Analyst Accuracy Matters

Not all Wall Street opinions carry equal weight. The analysts featured here have established track records of making correct calls, with accuracy rates ranging from 57% to 76%. That doesn't guarantee future success, but it does suggest these analysts have developed reliable frameworks for evaluating their coverage sectors.

For dividend-focused investors, these three healthcare stocks offer a combination of income generation and exposure to a sector with long-term demographic tailwinds. Healthcare demand tends to be relatively stable regardless of economic cycles, which can provide some portfolio ballast during uncertain times.

Of course, dividend yields should never be evaluated in isolation. A high yield can sometimes signal market skepticism about a company's future prospects. The analyst ratings provide additional context, helping investors distinguish between attractively valued opportunities and potential value traps.